Literature DB >> 32332301

68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient.

Liang Zhao1, Jianwei Gu2, Kaili Fu1, Qin Lin1, Haojun Chen2.   

Abstract

Ga-FAPI PET/CT was performed in a 56-year-old cirrhotic patient with multiple liver nodules, which were suspected of hepatocellular carcinoma by contrast-enhanced magnetic resonance but were not visualized by F-FDG PET/CT. Increased Ga-FAPI liver uptake was observed in this cirrhotic patient. However, the nodules had no pathological Ga-FAPI uptake and were clearly visualized due to the low activity compared with surrounding liver parenchyma. The Ga-FAPI PET/CT features, suggestive of benign nodules, have been later confirmed by histopathological examination. This case suggested that Ga-FAPI PET/CT may be useful in the differentiation between benign nodules and hepatocellular carcinoma in the patient with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32332301     DOI: 10.1097/RLU.0000000000003015

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis.

Authors:  Yue Zhou; Xin Yang; Huipan Liu; Wenbin Luo; Hanxiang Liu; Taiyong Lv; Junzheng Wang; Jianhua Qin; Santao Ou; Yue Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-07       Impact factor: 9.236

2.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 4.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

5.  68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer.

Authors:  Jipeng Yin; Bo Xin; Mingru Zhang; Xiaoli Hui; Na Chai; Hao Hu; Bing Xu; Jing Wang; Yongzhan Nie; Guangqing Zhou; Guanliang Wang; Hongbing Lu; Liping Yao; Liusheng Chen; Kaichun Wu
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

6.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

Review 7.  The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review.

Authors:  Okker D Bijlstra; Maud M E Boreel; Sietse van Mossel; Mark C Burgmans; Ellen H W Kapiteijn; Daniela E Oprea-Lager; Daphne D D Rietbergen; Floris H P van Velden; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; J Sven D Mieog; Lioe-Fee de Geus-Oei
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.